Document Type
Article
Date of Original Version
2013
Abstract
EpiVax, Inc., is an early-stage informatics and immunology biotechnology company in Providence, Rhode Island. It applies computational tools to harness immunity in three major areas: immunomodulation, biotherapeutic immunogenicity risk assessment and de-risking, and vaccine development. Immunotherapy, bio-better and vaccine candidates under development at EpiVax promise to improve the health outcomes of millions of people affected by devastating immune-related diseases.
Citation/Publisher Attribution
Moise, L., Marcello, A., Tassone, R., Cousens, L., Martin, W., & De Groot, A. S. (2013). Building Better Biotherapeutics and Vaccines by Design: EpiVax, Inc., Immunology Company. Rhode Island Medical Journal, 1(96),19-21.
Available at: http://rimed.org/rimedicaljournal/2013/02/2013-02-19-bio-epivax.pdf
Author Manuscript
This is a pre-publication author manuscript of the final, published article.
Terms of Use
This article is made available under the terms and conditions applicable
towards Open Access Policy Articles, as set forth in our Terms of Use.